New Therapeutic Agents in Thrombosis and Thrombolysis Book

	Preface
	Contributors
1	Overview of Hemostasis and Fibrinolysis	1
2	A Survey of Animal Modes to Develop New and Novel Antithrombotic Agents	9
3	Experimental Strategies for Assessing Antithrombotic Benefits and Hemorrhagic Risks of Novel Antithrombotic Agents	29
4	Design Issues in Clinical Trials of Thrombolytic and Antithrombotic Agents	49
5	Overview of New Developments in Heparins, Thrombin Inhibitors, and Other New and Novel Agents	77
6	Low-Molecular-Weight Heparins: Biochemistry and Pharmacology	87
7	Low-Molecular-Weight Heparins: Prophylaxis of Venous Thrombosis	103
8	Low-Molecular-Weight Heparins: Treatment of Venous Thromboembolism	129
9	Direct Thrombin Inhibitors: Active-Site Inhibitors of Thrombin	143
10	Direct Thrombin Inhibitors in Venous Thromboembolism	159
11	Direct Thrombin Inhibitors in Arterial Thrombosis	169
12	Direct Thrombin Inhibitors: Hirulog	191
13	Modulation of the Protein C Pathway as a Therapy for Thrombosis	209
14	Tissue Factor Pathway Inhibitor	225
15	Direct Factor Xa Inhibitors	261
16	Overview of Inhibition of Platelet Functions	285
17	Pharmacology and Clinical Development of Abciximab (c7E3 Fab, ReoPro): A Monoclonal Antibody Inhibitor of GPIIb/IIIa and [actual symbol not reproducible]	291
18	Clinical Use of a Monoclonal Antibody to the Platelet Glycoprotein IIb/IIIa Receptor	315
19	Integrilin: Synthetic Peptides Against the Platelet Glycoprotein IIb/IIIa Receptor	333
20	Tirofiban, a Nonpeptide Inhibitor of the Platelet Glycoprotein IIb/IIIA Receptor	355
21	Aurin Tricarboxylic Acid: Inhibitor of von Willebrand Factor Attachment to Platelet GPIb	367
22	Antagonism of Platelet Glycoprotein Ib Receptors: Protective Effects in Injured Coronary Arteries	385
23	Oxygen-Derived Free Radicals and Arterial Thrombosis	407
24	Platelet Procoagulant Activity	419
25	Development of Unstable Angina and Myocardial Infarction: Importance of Platelets, Platelet- and Endothelium-Derived Mediators, and Monocytes/Macrophages in Thrombosis, Vasoconstriction, and Neointimal Proliferation	435
26	Introduction to the Section on New Thrombolytic Agents	449
27	Animal Models to Assess the Safety and Efficacy of Thrombolytic Agents	451
28	Biochemistry, Pharmacology, and Initial Clinical Experience with TNK-tPa	475
29	Clinical and Preclinical Profile of the Novel Recombinant Plasminogen Activator Reteplase	495
30	Recombinant Urokinase (r-UK): Biochemistry, Pharmacology, and Clinical Experience	513
31	Pro-urokinase: History, Mechanisms of Action, and Clinical Development	539
32	Recombinant Glycosylated Pro-urkinase: Biochemistry, Pharmacology, and Early Clinical Experience	561
33	Recombinant Staphylokinase for Thrombolytic Therapy	591
34	Desmodus rotundus (Vampire Bat) Plasminogen Activator [actual symbol not reproducible]: A Superior Thrombolytic Created by Evolution	603
35	Antibody Targeting: A Strategy for Improving Thrombolytic Therapy	625
36	Thrombolytic Agents in Development	639
	Index	649